Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma

Neuro-Oncology

Volumn 16, Issue 1, 2014, Pages 38-49

  Shevtsov, Maxim A ^a   Yakovleva, Ludmila Y ^b   Nikolaev, Boris P ^b   Marchenko, Yaroslav Y ^b   Dobrodumov, Anatolii V ^c   Onokhin, Kirill V ^a   Onokhina, Yana S ^d   Selkov, Sergey A ^d   Mikhrina, Anastasiia L ^e   Guzhova, Irina V ^a   Martynova, Marina G ^a   Bystrova, Olga A ^a   Ischenko, Alexander M ^b   Margulis, Boris A ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b Institute for Highly Pure Biopreparations   (Russian Federation)

^c INSTITUTE OF MACROMOLECULAR COMPOUNDS   (Russian Federation)

^d D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

^e SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

glioma; Hsp70; magnetic nanoparticles; SPION; targeted delivery

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; GADOBUTROL; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE CONJUGATE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; MAGNETITE NANOPARTICLE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONJUGATE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; ELECTRON MICROSCOPE; GLIOMA; GLIOMA CELL; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MAGNETIC FIELD; MALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROMETER; PARTICLE SIZE; RAT; RELAXATION TIME; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BRAIN TUMOR; CHEMISTRY; DISEASE MODEL; ELECTRON MICROSCOPY; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TUMOR CELL CULTURE; WISTAR RAT;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 84891525236     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not141     Document Type: Article

References (52)

1. Mccarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60: 1241-1251
2. Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: An emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol. 2012;5:173-186
3. Salloum M, Ma R, Zhu L. Enhancement in treatment planning for magnetic nanoparticle hyperthermia: Optimization of the heat absorption pattern. Int J Hyperthermia. 2009;25:309-321
4. Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J. 2011;6:1342-1347
5. Jordan A, Scholz R, Maier-Hauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol. 2006;78:7-14
6. Ren Y, Zhang H, Chen B, et al. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine. 2012;7: 2261-2269
7. Basel M, Balivada S, Wang H, et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. Int J Nanomedicine. 2012;7: 297-306
8. Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int J Hyperthermia. 2007;23:315-323
9. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81:53-60
10. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastomamultiforme. J Neurooncol. 2011;103(2):317-324
11. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466
12. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26:3995-4021
13. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRvIII antibody conjugated iron oxide nanoparticles for MRI guided convectionenhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70:6303-6312
14. Chen BA, Cheng J, Shen MF, et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int J Nanomedicine. 2009;4:65-71
15. Nikolaev BP, Marchenko YY, Yakovleva LY, et al. Magnetic epidermal growth factor for targeted delivery to grafted tumor in mouse model. IEEE Trans Magn. 2013;49:1-7
16. Calderwood SK, Theriault JR, Gong J. Message in a bottle: Role of the 70 kDa HSP in anti-Tumor immunity. Eur J Cancer. 2005;35:2518-2527
17. Calderwood SK, Stevenson MA, Murshid A. Heat shock proteins, autoimmunity, and cancer treatment. Autoimmune Dis. 2012;2012: 486069
18. Murshid A, Gong J, Calderwood SK. The role of heat shock proteins in antigen cross presentation. Front Immunol. 2012;3:63
19. Wischhusen J, Schneider D, Mittelbronn M, et al. Death receptor-mediated apoptosis in human malignant glioma cells: Modulation by the CD40/CD40L system. J Neuroimmunol. 2005;162: 28-42
20. Zhang Y, Huang T, Hu Y, Wang Y. Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-kB signaling pathway. J Huazhong Univ Sci Technolog Med Sci. 2012;32:691-696
21. Tewari R, Choudhury SR, Mehta VS, Sen E. TNFa regulates the localization of CD40 in lipid rafts of glioma cells. Mol Biol Rep. 2012; 39:8695-8699
22. Srivastava PK, Callahan MK, Mauri MM. Treating human cancers with heat shock protein-peptide complexes: The road ahead. Expert Opin Biol Ther. 2009;9:179-186
23. Ito A, Matsuoka F, Honda H, Kobayashi T. Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother. 2004;53:26-32
24. Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 1981;17:1247-1248
25. Lazarev VF, Onokhin KV, Antimonova OI, et al. Kinetics of chaperone activity of proteins Hsp70 and Hdj1 in human leukemia U937 cells after preconditioning with thermal shock or compound U133. Biochemistry (Moscow). 2011;76:590-595
26. Binder RJ, Harris ML, Menoret A, Srivastava PK. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ Cells. J Immunol. 2000;165:2582-2587
27. Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med. 2011;17:130-134
28. Rosen JE, Chan L, Shieh DB, Gu FX. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine. 2012;8:275-290
29. Murshid A, Gong J, Calderwood SK. Heat shock protein 90 mediates efficient antigen cross-presentation through the scavenger receptor expressed by endothelial cells-I. J Immunol. 2010;185:2903-2917
30. Calderwood SK, Theriault J, Gray PJ, Gong J. Cell surface receptors for molecular chaperones. Methods. 2007;43:199-206
31. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 2002;17:353-362
32. Theriault JR, Adachi H, Calderwood SK. Role of scavenger receptors in the binding and internalization of heat shock protein 70. J Immunol. 2006;177:8604-8611
33. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2010; 89:216-224
34. Graham LM, Brown GD. The Dectin-2 family of C-Type lectins in immunity and homeostasis. Cytokine. 2009;48:148-155
35. den Dunnen J, Gringhuis SI, Geijtenbeek TB. Innate signaling by the C-Type lectin DC-SIGN dictates immune responses. Cancer Immunol Immunother. 2009;58:1149-1157
36. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins Gp96, Hsp90, Hsp70, and calreticulin. Immunity. 2001;14:303-313
37. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000;6:435-442
38. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002;277:15107-15112
39. Becker T, Hartl FU, Wieland F. CD40,anextracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol. 2002;158: 1277-1285
40. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120(5): 649-661
41. Kratsovnik E, Bromberg Y, Sperling O, Zoref-Shani E. Oxidative stress activates transcription factor NF-kB-mediated protective signaling in primary rat neuronal cultures. J Mol Neurosci. 2005;26(1):27-32
42. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 2006;13(5):730-737
43. Temkin V, Karin M. From death receptor to reactive oxygen species and cJun N-Terminal protein kinase: The receptor-interacting protein 1 odyssey. Immunol Rev. 2007;220(1):8-21
44. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN. LPS induces CD40 gene expression through the activation of NF-kB and STAT-1a in macrophages and microglia. Blood. 2005;106:3114-3122
45. Abkin SV, Pankratova KM, Komarova EY, Guzhova IV, Margulis BA.Hsp70 chaperone-based gel composition as a novel immunotherapeutic anti-Tumor tool. Cell Stress Chaperones. 2013;18:391-396
46. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci. 2002; 115:2603-2611
47. Broquet AH, Thomas G, Masliah J, Trugnan G, Bachelet M. Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release. J Biol Chem. 2003; 278:21601-21606
48. Gehrmann M, Liebisch G, Schmitz G, et al. Tumor-specific hsp70plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One. 2008;3(4):e1925
49. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neurooncol. 2000;50:99-108
50. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95
51. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29:487-496
52. Agemy L, Friedmann-Morvinski D, Kotamraju VR, et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A. 2011;108:17450-17455